All India Institute of Medical Sciences

Department of Biotechnology

National Brain Research Centre

International Center for Genetic and Biotechnology

All India Institute of Medial Sciences (aiims)

National Brain Research Centre (nbrc)

Department of Biotechnology (dbt)

International Centre for Genetic Engineering and Biotechnology

Subrata Sinha

Kunzang Chosdol

Navin Khanna

Bhawana Dikshit

Imran Khan

Parthaprasad Chattopadhyay

Ashutosh Tiwari

Mohammad Khalid Zakaria

Subrat K Acharya

The present invention relates to cell specific therapeutic modality by using a region of the PLAP Promoter. The invention further relates to specific expression of therapeutically PLAP useful sequences for specific transcriptional activation of this gene. The invention also relates to the PLAP region which may be used alone or in combination with other regions like enhancer sequences that augment cell or tumour specific gene expression.

Placental like alkaline phosphatase (PLAP) promoter mediated cell targeting

This invention relates to a high affinity recombinant humanized antibody fragment (scFv) specific for hepatitis B surface antigen having unique inter/intra chain bonding interaction because of 28 altered amino acid residues from the original mouse (5S) antibody and its chimeric Fab form, wherein fine tuning of the vernier zone residue makes it closer to the human sequence without any structural constraints.

Humanized high affinity recombinant antibody against Hepatitis B surface antigen

The present invention demonstrates for the first time that FAT1 plays an important role in modulating PDCD4 expression, which in turn regulates AP-1 dependent transcription, controls processes crucial for migration and invasion in cancer cells, controls induction of a pro-inflammatory micro environment in cancer cells. The study illustrates a link between inflammation and cancer in cells or in a subject. This work highlights the importance of FAT1 in the induction of the cellular pathways of migration and invasion, proteolysis of the ECM and the expression of pro-inflammatory molecules leading to a favorable micro environment for tumor and cancer progression. The present invention also provides the use of FAT1 in regulating neoplastic phenotypes and genotypes including invasiveness and inflammatory micro environment of the cancer cells by acting as a novel apical regulator of a signaling pathway by affecting the AP1 transcriptional activity, affecting the property of both cell migration and invasion and at the same time affecting the expression of inflammatory modulators. The present invention also identifies a novel regulatory pathway for inflammatory mediators and inflammatory cellular responses via PDCD4 and AP1. The invention describes a pathway for the upregulation of inflammatory processes as such, and hence a means of regulating inflammatory pathologies in general.

[object Object]

Growing community of inventors

Haryana, India

Subrata Sinha